Ushbu ish iqtibos qilgan ishlar

189 ta ish

Ish: Innovations in cancer immunotherapy: A comprehensive overview of recent breakthroughs and future directions

Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles
Marina Colombo, Graça Raposo, Clotilde Théry
Sharh maqola201412 iqtibos
ABI
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
Sharh maqola20127 iqtibos
ABI
Extracellular vesicles: Exosomes, microvesicles, and friends
Graça Raposo, Willem Stoorvogel
Sharh maqola20135 iqtibos
ABI
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje, Jesús G. Berdeja, Yi Lin +20
Maqola20194 iqtibos
ABI
CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity
Wenyan Fu, Changhai Lei, Shuowu Liu +12
Maqola20194 iqtibos
ABI
Delivery technologies for cancer immunotherapy
Rachel Riley, Carl H. June, Róbert Langer +1
Sharh maqola20193 iqtibos
ABI
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Philip W. Kantoff, Celestia S. Higano, Neal D. Shore +10
Maqola20103 iqtibos
ABI
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp, Michael Kalos, David M. Barrett +10
Maqola20133 iqtibos
ABI
CTLA-4 and PD-1 Pathways
Elizabeth I. Buchbinder, Anupam M. Desai
Sharh maqola20153 iqtibos
ABI
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Dai Fukumura, Jonas Kloepper, Zohreh Amoozgar +2
Sharh maqola20183 iqtibos
ABI
Macrophages as regulators of tumour immunity and immunotherapy
David G. DeNardo, Brian Ruffell
Sharh maqola20193 iqtibos
ABI
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Ju‐Yeun Lee, Hyun Tae Lee, Woo‐Ri Shin +11
Maqola20162 iqtibos
ABI
Going viral with cancer immunotherapy
Brian D. Lichty, Caroline J. Breitbach, David F. Stojdl +1
Sharh maqola20142 iqtibos
ABI
Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Caroline J. Breitbach, Rozanne Arulanandam, Naomi De Silva +15
Maqola20132 iqtibos
ABI
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio +26
Maqola20152 iqtibos
ABI
Viral vectors: a look back and ahead on gene transfer technology.
Laura Vannucci, Michele Lai, Flavia Chiuppesi +2
Maqola20132 iqtibos
ABI
Sarlavhasiz
Boshqa2 iqtibos
ABI
Dendritic cells in cancer immunology and immunotherapy
Stefanie K. Wculek, Francisco J. Cueto, Adriana M. Mujal +3
Sharh maqola20192 iqtibos
ABI
Injectable dual-scale mesoporous silica cancer vaccine enabling efficient delivery of antigen/adjuvant-loaded nanoparticles to dendritic cells recruited in local macroporous scaffold
Thanh Loc Nguyen, Bong Geun, Young‐Jin Choi +2
Maqola20202 iqtibos
ABI
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen, Ira Mellman
Sharh maqola20132 iqtibos
ABI
Cancer immunotherapy comes of age
Ira Mellman, George Coukos, Glenn Dranoff
Sharh maqola20112 iqtibos
ABI
The future of immune checkpoint therapy
Padmanee Sharma, James P. Allison
Sharh maqola20152 iqtibos
ABI
Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study
Mei‐Hwei Chang, San‐Lin You, Chien‐Jen Chen +9
Maqola20092 iqtibos
ABI
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Antonio Di Stasi, Siok‐Keen Tey, Gianpietro Dotti +17
Maqola20112 iqtibos
ABI
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.
G. Fyfe, Richard I. Fisher, S A Rosenberg +3
Maqola19952 iqtibos
ABI